Novavax’s COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses in Phase 3 Trial
| | | | |

Novavax’s COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses in Phase 3 Trial

On Jun. 11, 2025, Novavax announced results of the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alone trivalent…

U.S.  Implements New Export Controls to Address National Security Risks Related to Biotechnology
| | | | | | | | | | | |

U.S. Implements New Export Controls to Address National Security Risks Related to Biotechnology

On Jan. 15, 2025, the U.S. Department of Commerce’s Bureau of Industry and Security (BIS) released an Interim…